Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter H Jones

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Data in Brief|April 8, 2016
A dataset to assess providers׳ knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management GuidelineYashashwi Pokharel, Lynne Steinberg, Winston Chan, et al.
Atherosclerosis|January 17, 2016
Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management GuidelineYashashwi Pokharel, Lynne Steinberg, Winston Chan, et al.
Atherosclerosis|November 11, 2008
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 studyPeter H Jones, Michael H Davidson, Moti L Kashyap, et al.
The Journal of Clinical Endocrinology and Metabolism|June 8, 2004
Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restrictionAntonios M Xydakis, Christopher C Case, Peter H Jones, et al.
Cardiology and Therapy|June 22, 2020
A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 StudiesMichael J Koren, Peter H Jones, Jennifer G Robinson, et al.
Atherosclerosis|January 28, 2019
Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities studyAnum Saeed, Wensheng Sun, Anandita Agarwala, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 8, 2010
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind studyEli M Roth, James M McKenney, Maureen T Kelly, et al.
Journal of Clinical Lipidology|February 5, 2011
Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemiaHarold E Bays, Peter H Jones, Syed M Mohiuddin, et al.
The American Journal of Cardiology|July 25, 2008
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelinesMichael H Davidson, Marshall A Corson, Mark J Alberts, et al.
Journal of Clinical Lipidology|February 5, 2011
Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studiesPeter H Jones, Michael H Davidson, Anne C Goldberg, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Data in Brief|April 8, 2016
A dataset to assess providers׳ knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management GuidelineYashashwi Pokharel, Lynne Steinberg, Winston Chan, et al.
Atherosclerosis|January 17, 2016
Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management GuidelineYashashwi Pokharel, Lynne Steinberg, Winston Chan, et al.
Atherosclerosis|November 11, 2008
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 studyPeter H Jones, Michael H Davidson, Moti L Kashyap, et al.
The Journal of Clinical Endocrinology and Metabolism|June 8, 2004
Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restrictionAntonios M Xydakis, Christopher C Case, Peter H Jones, et al.
Cardiology and Therapy|June 22, 2020
A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 StudiesMichael J Koren, Peter H Jones, Jennifer G Robinson, et al.
Atherosclerosis|January 28, 2019
Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities studyAnum Saeed, Wensheng Sun, Anandita Agarwala, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 8, 2010
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind studyEli M Roth, James M McKenney, Maureen T Kelly, et al.
Journal of Clinical Lipidology|February 5, 2011
Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemiaHarold E Bays, Peter H Jones, Syed M Mohiuddin, et al.
The American Journal of Cardiology|July 25, 2008
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelinesMichael H Davidson, Marshall A Corson, Mark J Alberts, et al.
Journal of Clinical Lipidology|February 5, 2011
Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studiesPeter H Jones, Michael H Davidson, Anne C Goldberg, et al.
Pageof 11